scholarly journals Comparison of annual percentage change in breast cancer incidence rate between Taiwan and the United States-A smoothed Lexis diagram approach

2017 ◽  
Vol 6 (7) ◽  
pp. 1762-1775 ◽  
Author(s):  
Li-Hsin Chien ◽  
Tzu-Jui Tseng ◽  
Chung-Hsing Chen ◽  
Hsin-Fang Jiang ◽  
Fang-Yu Tsai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Incidence Rate ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Annual Percentage Change ◽  
Cancer Incidence Rate ◽  
Lexis Diagram ◽  
Diagram Approach

Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998

2003 ◽  
Vol 21 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Christopher I. Li ◽  
Janet R. Daling ◽  
Kathleen E. Malone
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Receptor ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Incidence Rates

Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis. Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds. Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.

Breast Cancer

2018 ◽  
Author(s):  
Nancy E Davidson
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Replacement ◽  
Breast Cancer Incidence ◽  
Stage Iv ◽  
The United States ◽  
Rate Of Increase ◽  
Stage Iv Breast Cancer ◽  
Incidence And Mortality

Invasive breast cancer, the most common nonskin cancer in women in the United States, will be diagnosed in 266,120 In 2018, along with 63,960 new cases of non-invasive (in situ) breast cancer. Incidence and mortality reached a plateau and appear to be dropping in both the United States and parts of western Europe. This decline has been attributed to several factors, such as early detection through the use of screening mammography and appropriate use of systemic adjuvant therapy, as well as decreased use of hormone replacement therapy. However, the global burden of breast cancer remains great, and global breast cancer incidence increased from 641,000 in 1980 to 1,643,000 in 2010, an annual rate of increase of 3.1%. This chapter examines the etiology, epidemiology, prevention, screening, staging, and prognosis of breast cancer. The diagnoses and treatments of the four stages of breast cancer are also included. Figures include algorithms used for the systemic treatment of stage IV breast cancer and hormone therapy for women with stage IV breast cancer. Tables describe selected outcomes from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 chemoprevention trials, tamoxifen chemoprevention trials for breast cancer, the TNM staging system and stage groupings for breast cancer, some commonly used adjuvant chemotherapy regimens, an algorithm for suggested treatment for patients with operable breast cancer from the 2011 St. Gallen consensus conference, guidelines for surveillance of asymptomatic early breast cancer survivors from the American Society of Clinical Oncology, and newer agents for metastatic breast cancer commercially available in the United States. This review contains 2 highly rendered figures, 8 tables, and 108 references.

scholarly journals An Expanded Agenda for the Primary Prevention of Breast Cancer: Charting a Course for the Future

2020 ◽  
Vol 17 (3) ◽  
pp. 714 ◽  
Author(s):  
Mary C. White ◽  
Marion (Mhel) H. E. Kavanaugh-Lynch ◽  
Shauntay Davis-Patterson ◽  
Nancy Buermeyer
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Prevention ◽  
Cancer Diagnosis ◽  
Cancer Incidence ◽  
Cancer Survival ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Breast Cancer Prevention ◽  
The Future

Advances in breast cancer science, early detection, and treatment have resulted in improvements in breast cancer survival but not in breast cancer incidence. After skin cancer, breast cancer is the most common cancer diagnosis in the United States. Each year, nearly a quarter million U.S. women receive a breast cancer diagnosis, and the number continues to rise each year with the growth in the population of older women. Although much remains to be understood about breast cancer origins and prevention, action can be taken on the existing scientific knowledge to address the systemic factors that drive breast cancer risk at the population level. The California Breast Cancer Research Program funded a team at Breast Cancer Prevention Partners (BCPP) to convene leaders in advocacy, policy, and research related to breast cancer prevention from across the state of California. The objective was the development of a strategic plan to direct collective efforts toward specific and measurable objectives to reduce the incidence of breast cancer. The structured, innovative approach used by BCPP to integrate scientific evidence with community perspectives provides a model for other states to consider, to potentially change the future trajectory of breast cancer incidence in the United States.

scholarly journals Clustering 46 Asian countries according to the trend of breast cancer incidence rate from 1990- 2016: An application of growth mixture model

2020 ◽  
Author(s):  
Fariba Azadikhah ◽  
Kamran Mehrabani ◽  
Hadi Raeisi Shahraki
Keyword(s):  
Breast Cancer ◽  
Incidence Rate ◽  
Mixture Model ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Asian Countries ◽  
Cancer Incidence Rate ◽  
Growth Mixture Model ◽  
Growth Mixture ◽  
Cluster 2

Abstract Breast cancer among Asian countries is the second cause of cancer death and remains as a challenging issue in woman health as 39% of all new cases of breast cancer have been diagnosed in Asia. The current study was devoted to recognize different patterns of breast cancer incidence rate among Asian countries. Information about the incidence rates of female breast cancer within 1990-2016 years was extracted from Gapminder web site and growth mixture model was developed to describe the growth patterns and provide a set of tools to investigate the individual differences in change. Our findings suggest an overall increasing trend throughout the continent, but individual trajectories show different behaviors among countries. Bayesian information creation showed that 3-cluster model was the best. Cluster one countries including: Bangladesh, Israel, Kyrgyz republic, Maldives, Nepal, North Korea, Tajikistan and Timor-Leste, the slope of -0.13 suggests a slight negative trend for the incidence rate of breast cancer. 17 countries including: Armenia, Bahrain, Brunei, Cyprus, Iraq, Japan, Jordan, Kazakhstan, Kuwait, Lebanon, Malaysia, Pakistan, Philippines, Qatar, Singapore, South Korea, United Arab Emirate which belongs to cluster 2, had not only a high intercept that means higher amounts of incidence rate in 1990 year, but also a slope of 0.96, indicating a sharp increase trajectory. Also slope of 0.38 showed a slow increase in the incidence rate of breast cancer over time for another 21 countries. In conclusion, increase of breast cancer incidence among cluster 2 countries is tremendous therefore effective strategies for prevention are urgently needed.

Sign in / Sign up

Export Citation Format

Share Document